2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-158161
    SLC6A19-IN-1 3032920-98-9 98%
    SLC6A19-IN-1 is a potent and highly selective inhibitor and transport corrector of human SLC6A19 (IC50=47 nM). Furthermore, at a concentration of 35 μM, SLC6A19-IN-1 exhibits no activity against SLC1A5, SLC7A5, or SLC6A8. SLC6A19-IN-1 is applicable to research on phenylketonuria (PKU) and hyperphenylalaninemia. SLC6A19-IN-1 is also suitable for studies related to various metabolic disorders, including tyrosinemia, maple syrup urine disease, urea cycle disorders, and hyperammonemia.
    SLC6A19-IN-1
  • HY-158571
    17-Phenoxy trinor prostaglandin F2α 2162157-41-5 98%
    17-Phenoxy trinor prostaglandin F2α is a PGF2α analog.
    17-Phenoxy trinor prostaglandin F2α
  • HY-158639
    12-POHSA 2042646-31-9 98%
    12-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 12-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration.
    12-POHSA
  • HY-158697
    α-Glucosidase-IN-65 98%
    α-Glucosidase-IN-65 (compound 5) is a Schiff base derivative of 3,4-dihydroxyphenylacetic acid. α-Glucosidase-IN-65 is a potent α-glucosidase inhibitor, with an IC50 of 12.84 μM.
    α-Glucosidase-IN-65
  • HY-158722
    Caerulein acetate 2760881-68-1 98%
    Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.
    Caerulein acetate
  • HY-158803
    C6 Biotin glucosylceramide (d18:1/6:0) 2692623-22-4 98%
    C6 Biotin glucosylceramide (d18:1/6:0) (C6 Glucosylceramide-biotin; N-Hexanoyl-biotin-glucosylceramide) is an ester product.
    C6 Biotin glucosylceramide (d18:1/6:0)
  • HY-158944
    1,2-Dipalmitoleoyl-3-11(Z)-octadecenoyl-rac-glycerol 2692623-04-2 98%
    1,2-Dipalmitoleoyl-3-11(Z)-octadecenoyl-rac-glycerol is a triacylglycerol that contains cis-Vaccenic acid (HY-113427A) and Palmitoleic acid (HY-W011873).
    1,2-Dipalmitoleoyl-3-11(Z)-octadecenoyl-rac-glycerol
  • HY-158952
    C24 (2'(R)-Hydroxy) dihydro ceramide (d18:0/24:0) 164989-36-0 98%
    C24 (2'(R)-Hydroxy) dihydro ceramide (d18:0/24:0) ((R)-2'-Hydroxy cer(d18:0/24:0)) is the 2R-isomer of a 2’-hydroxylated form of C24 Dihydro ceramide (d18:0/24:0) (HY-156206).
    C24 (2'(R)-Hydroxy) dihydro ceramide (d18:0/24:0)
  • HY-159004
    Se-DOPE 98%
    Se-DOPE is a phospholipid molecule with selenium. Se-DOPE can be used to synthesize the bifunctional Janus liposozyme. Se-DOPE promotes the production of ROS with induction of lights, scavenges the ROS with the presence of glutathione. Se-DOPE regulates redox and immune homeostasis in infected diabetic wounds.
    Se-DOPE
  • HY-159007
    BD-AcAc2 58213-75-5 98%
    BD-AcAc2 (R,S-1,3-Butanediol acetoacetate diester) is an orally active, CNS-penetrant antiepileptic agent. BD-AcAc2 inhibits NF-κB, NLRP3 inflammasome, caspase-1/3, pyroptosis, apoptosis, and enhances autophagy. BD-AcAc2 exhibits antioxidant activity by modulating ROS, MDA, SOD, and GSH levels, and alleviates oxidative stress. BD-AcAc2 mitigates chronic colitis, counteracts Dextran Sodium Sulfate (DSS)-induced pathology, protects against central nervous system oxygen toxicity and acute lung injury, and exhibits anti-seizure efficacy. BD-AcAc2 can be used for the research of colitis, sarcopenia, acute lung injury, seizure, and obesity.
    BD-AcAc2
  • HY-159196
    1α,25-Dihydroxy-24-oxocholecalciferol 76338-50-6 98%
    1α,25-Dihydroxy-24-oxocholecalciferol is the C-24 oxidative metabolite of 1,25-dihydroxycholecalciferol.
    1α,25-Dihydroxy-24-oxocholecalciferol
  • HY-159201
    24-Oxo-25-hydroxyvitamin D3 74886-61-6 98%
    24-Oxo-25-hydroxyvitamin D3 is a vitamin D3 metabolite and an intermediate in the renal mitochondrial side-chain oxidation pathway. 24-Oxo-25-hydroxyvitamin D3 enhances intestinal calcium transport in rats. 24-Oxo-25-hydroxyvitamin D3 can be used in studies related to X-linked hypophosphatemic rickets.
    24-Oxo-25-hydroxyvitamin D3
  • HY-159491
    DPP-4-IN-11 98%
    DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM).
    DPP-4-IN-11
  • HY-159494
    PROTAC sEH-degrader-1 98%
    sEH-degrader-1 (Compound 8) serves as an inhibitor for sEH, with IC50 values of 3.8 nM and 210 nM against hsEH and msEH respectively. sEH-degrader-1 can effectively degrade sEH in mouse liver and brown adipose tissue (Red: UC-1728 (HY-114266), black: linker (HY-W248248), Blue: Thalidomide-5-piperazine (HY-W834174)).
    PROTAC sEH-degrader-1
  • HY-159495
    Keap1-Nrf2-IN-21 98%
    Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC50=2.60 μM).
    Keap1-Nrf2-IN-21
  • HY-159496
    Dyrk1A-IN-10 2891824-14-7 98%
    Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar.
    Dyrk1A-IN-10
  • HY-159530
    Darbinuradum 1877347-38-0 98%
    Darbinuradum (Darbinurad) is a urate transporter inhibitor.
    Darbinuradum
  • HY-159658
    TTR stabilizer 1 2778162-15-3 98%
    TTR stabilizer 1 (compound 1) is a Transthyretin (TTR) stabilizer, with an EC50 of 0.031 μM.
    TTR stabilizer 1
  • HY-159691
    IONIS-FGFR4Rx 1416376-17-4 98%
    IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases.
    IONIS-FGFR4Rx
  • HY-159694
    IONIS PTP1BRx 1403406-29-0 98%
    IONIS PTP1BRx (ISIS 404173) is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity.
    IONIS PTP1BRx
Cat. No. Product Name / Synonyms Application Reactivity